Trial Information

Summary: Adults with Melanoma Sought for Clinical Trial

The Human Immune Therapy Center of the Cancer Center at the University of Virginia Health System invites adults with melanoma to enroll in a research study.

The purpose of the study is to test investigational vaccines to see if they are safe to use in people with melanoma. Prior to, during, and after enrollment, physical examinations, blood tests, CT scans, skin and eye exams, and at week 4, sentinel node biopsy will be required. If enrolled, subjects will be randomly assigned to 1 of 4 groups. Each group will receive a vaccine with a differing formulation. The study involves 6 vaccine treatments over 7 weeks. If the results of these 6 treatments are favorable, participants become eligible to receive 18 booster vaccinations over an additional 2-year time period. All those enrolled will have blood drawn and physical exams during return visits to monitor general health and response to study vaccines. Participants will be followed for five years after the cessation of treatment to monitor for long-term side effects.

Participant or participant's insurance will be responsible for the cost of required procedures. There will be no financial compensation for study completion.

For more information, please contact:

Emily Stell, 434-982-6584
or email ems2b@virginia.edu
Principal Investigator: Craig Slingluff, MD
HIC 11688/ECOG E1602




www.healthsystem.virginia.edu/clinical_trials

If you would like to learn more about participating in this study, please send an e-mail message using the form below.